Evolving Tumor Characteristics and Smart Nanodrugs for Tumor Immunotherapy

References

• Roehlen N, Muller M, Nehme Z, et al. Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment. J Hepatol. 2023;78(2):343–355. doi:10.1016/j.jhep.2022.10.011
   PubMed Web of Science ®Google Scholar
• Cillo AR, Kurten CHL, Tabib T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183–199 e9. doi:10.1016/j.immuni.2019.11.014
   PubMed Web of Science ®Google Scholar
• Cheng Z, Li M, Dey R, Chen Y. Nanomaterials for cancer therapy: current progress and perspectives. J Hematol Oncol. 2021;14(1):85. doi:10.1186/s13045-021-01096-0
   PubMed Web of Science ®Google Scholar
• Peng S, Xiao F, Chen M, Gao H. Tumor-microenvironment-responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2022;9(1):e2103836. doi:10.1002/advs.202103836
   Web of Science ®Google Scholar
• Yang G, Xu L, Chao Y, et al. Hollow MnO(2) as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017;8(1):902. doi:10.1038/s41467-017-01050-0
   PubMedGoogle Scholar
• Jia X, Zhang Y, Zou Y, et al. Dual Intratumoral Redox/Enzyme-Responsive NO-releasing nanomedicine for the specific, high-efficacy, and low-toxic cancer therapy. Adv Mater. 2018;30(30):e1704490. doi:10.1002/adma.201704490
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen S, Zhu J. Hydrogen bond-mediated supramolecular polymeric nanomedicine with pH/Light-responsive methotrexate release and synergistic chemo-/photothermal therapy. Biomacromolecules. 2022;23(10):4230–4240. doi:10.1021/acs.biomac.2c00717
   PubMed Web of Science ®Google Scholar
• Liu Y, Jin J, Xu H, et al. Construction of a pH-responsive, ultralow-dose triptolide nanomedicine for safe rheumatoid arthritis therapy. Acta Biomater. 2021;121:541–553. doi:10.1016/j.actbio.2020.11.027
   PubMed Web of Science ®Google Scholar
• Gao H, Bi Y, Wang X, et al. Near-infrared guided thermal-responsive nanomedicine against orthotopic superficial bladder cancer. ACS Biomater Sci Eng. 2017;3(12):3628–3634. doi:10.1021/acsbiomaterials.7b00405
   PubMed Web of Science ®Google Scholar
• Wang X, Sun B, Ye Z, et al. Enzyme-Responsive COF-based thiol-targeting nanoinhibitor for curing bacterial infections. ACS Appl Mater Interfaces. 2022;14(34):38483–38496. doi:10.1021/acsami.2c08845
   PubMed Web of Science ®Google Scholar
• Sa P, Sahoo SK, Dilnawaz F. Responsive role of nanomedicine in the tumor microenvironment and cancer drug resistance. Curr Med Chem. 2022. doi:10.2174/0929867329666220922111336
   PubMed Web of Science ®Google Scholar
• Mendes BB, Sousa DP, Conniot J, Conde J. Nanomedicine-based strategies to target and modulate the tumor microenvironment. Trends Cancer. 2021;7(9):847–862. doi:10.1016/j.trecan.2021.05.001
   PubMed Web of Science ®Google Scholar
• Iyer AK, Singh A, Ganta S, Amiji MM. Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev. 2013;65(13–14):1784–1802. doi:10.1016/j.addr.2013.07.012
   PubMed Web of Science ®Google Scholar
• Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715. doi:10.1016/j.drup.2020.100715
   PubMed Web of Science ®Google Scholar
• Manabe T, Bivona TG. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer. J Clin Invest. 2022;132(4). doi:10.1172/JCI156891
   PubMed Web of Science ®Google Scholar
• Liu HH, Zhang ZY, Song L, Gao J, Liu YF. Lipid metabolism of cancer stem cells. Oncol Lett. 2022;23(4). doi:10.3892/ol.2022.13239
   Web of Science ®Google Scholar
• Chen D, Zhang X, Li Z, Zhu B. Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. Theranostics. 2021;11(3):1016–1030. doi:10.7150/thno.51777
   PubMed Web of Science ®Google Scholar
• Liu Y, Tiruthani K, Wang M, et al. Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. Nanoscale Horiz. 2021;6(4):319–329. doi:10.1039/d0nh00588f
   PubMed Web of Science ®Google Scholar
• Lan Q, Lai W, Zeng Y, et al. CCL26 Participates in the PRL-3-induced promotion of colorectal cancer invasion by stimulating tumor-associated macrophage infiltration. Mol Cancer Ther. 2018;17(1):276–289. doi:10.1158/1535-7163.MCT-17-0507
   PubMed Web of Science ®Google Scholar
• Qin S, LaRosa G, Campbell JJ, et al. Expression of monocyte chemoattractant protein-1 and interleukin-8 receptors on subsets of T cells: correlation with transendothelial chemotactic potential. Eur J Immunol. 1996;26(3):640–647. doi:10.1002/eji.1830260320
   PubMed Web of Science ®Google Scholar
• Wang YC, Tsai SH, Chen MH, et al. Mineral nanomedicine to enhance the efficacy of adjuvant radiotherapy for treating osteosarcoma. ACS Appl Mater Interfaces. 2022;14(4):5586–5597. doi:10.1021/acsami.1c21729
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer. 2012;12(7):487–493. doi:10.1038/nrc3298
   PubMed Web of Science ®Google Scholar
• van der Meel R, Sulheim E, Shi Y, Kiessling F, Mulder WJM, Lammers T. Smart cancer nanomedicine. Nat Nanotechnol. 2019;14(11):1007–1017. doi:10.1038/s41565-019-0567-y
   PubMed Web of Science ®Google Scholar
• Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res. 2019;52(6):1543–1554. doi:10.1021/acs.accounts.9b00148
   PubMed Web of Science ®Google Scholar
• Peng M, Mo Y, Wang Y, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18(1):128. doi:10.1186/s12943-019-1055-6
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lu M, Qin Y, et al. Neoantigen: a new breakthrough in tumor immunotherapy. Front Immunol. 2021;12:672356. doi:10.3389/fimmu.2021.672356
   PubMed Web of Science ®Google Scholar
• Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–229. doi:10.1038/s41571-020-00460-2
   PubMed Web of Science ®Google Scholar
• Lybaert L, Lefever S, Fant B, et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023;41(1):15–40. doi:10.1016/j.ccell.2022.10.013
   PubMed Web of Science ®Google Scholar
• Musetti S, Huang L. Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy. ACS Nano. 2018;12(12):11740–11755. doi:10.1021/acsnano.8b05893
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. doi:10.1038/s41423-020-0488-6
   PubMed Web of Science ®Google Scholar
• Zhang QL, Hong S, Dong X, et al. Bioinspired nano-vaccine construction by antigen pre-degradation for boosting cancer personalized immunotherapy. Biomaterials. 2022;287:121628. doi:10.1016/j.biomaterials.2022.121628
   PubMed Web of Science ®Google Scholar
• Huang D, Wu T, Lan S, Liu C, Guo Z, Zhang W. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors. Biomaterials. 2022;289:121808. doi:10.1016/j.biomaterials.2022.121808
   PubMed Web of Science ®Google Scholar
• Kinkead HL, Hopkins A, Lutz E, et al.. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. JCI Insight. 2018;3(20). doi:10.1172/jci.insight.122857
   PubMed Web of Science ®Google Scholar
• Park KS, Nam J, Son S, Moon JJ. Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8(+) T cells. Biomaterials. 2021;274:120844. doi:10.1016/j.biomaterials.2021.120844
   PubMed Web of Science ®Google Scholar
• Hu Z, Leet DE, Allesoe RL, et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021;27(3):515–525. doi:10.1038/s41591-020-01206-4
   PubMed Web of Science ®Google Scholar
• Nam J, Son S, Park KS, Moon JJ. Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis. Adv Ther. 2021;4:8.
   Google Scholar
• Sha H, Liu Q, Xie L, et al. Case report: pathological complete response in a lung metastasis of phyllodes tumor patient following treatment containing peptide neoantigen nano-vaccine. Front Oncol. 2022;12:800484. doi:10.3389/fonc.2022.800484
   PubMed Web of Science ®Google Scholar
• Shae D, Baljon JJ, Wehbe M, et al. Co-delivery of peptide neoantigens and stimulator of interferon genes agonists enhances response to cancer vaccines. ACS Nano. 2020;14(8):9904–9916. doi:10.1021/acsnano.0c02765
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Zhao B, et al. Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency. Adv Sci. 2022;9(11):e2105631. doi:10.1002/advs.202105631
   Web of Science ®Google Scholar
• Liu Q, Chu Y, Shao J, et al. Benefits of an immunogenic personalized neoantigen nanovaccine in patients with high-risk gastric/gastroesophageal junction cancer. Adv Sci (Weinh). 2022;10(1):e2203298. doi:10.1002/advs.202203298
   PubMedGoogle Scholar
• Selvanesan BC, Chandra D, Quispe-Tintaya W, et al. Listeria delivers tetanus toxoid protein to pancreatic tumors and induces cancer cell death in mice. Sci Transl Med. 2022;14(637):eabc1600. doi:10.1126/scitranslmed.abc1600
   PubMed Web of Science ®Google Scholar
• Zhang W, Shi Y, Li H, et al. In situ injectable nano-complexed hydrogel based on chitosan/dextran for combining tumor therapy via hypoxia alleviation and TAMs polarity regulation. Carbohydr Polym. 2022;288:119418. doi:10.1016/j.carbpol.2022.119418
   PubMed Web of Science ®Google Scholar
• Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770–2788. doi:10.1016/j.cell.2022.06.035
   PubMed Web of Science ®Google Scholar
• Cheng K, Zhao R, Li Y, et al. Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. Nat Commun. 2021;12(1):2041. doi:10.1038/s41467-021-22308-8
   PubMed Web of Science ®Google Scholar
• Younis NK, Roumieh R, Bassil EP, Ghoubaira JA, Kobeissy F, Eid AH. Nanoparticles: attractive tools to treat colorectal cancer. Semin Cancer Biol. 2022;86(Pt 2):1–13. doi:10.1016/j.semcancer.2022.08.006
   PubMedGoogle Scholar
• Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. doi:10.1186/s12943-021-01428-1
   PubMed Web of Science ®Google Scholar
• Zhang N, Zhang H, Wu W, et al. Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma. Theranostics. 2022;12(13):5931–5948. doi:10.7150/thno.74281
   PubMed Web of Science ®Google Scholar
• Oh DY, Fong L. Cytotoxic CD4(+) T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54(12):2701–2711. doi:10.1016/j.immuni.2021.11.015
   PubMed Web of Science ®Google Scholar
• Zhang D, Lin Z, Wu M, et al. Cytosolic delivery of thiolated neoantigen nano-vaccine combined with immune checkpoint blockade to boost anti-cancer T cell immunity. Adv Sci. 2021;8(6):2003504. doi:10.1002/advs.202003504
   Web of Science ®Google Scholar
• Mohsen MO, Vogel M, Riether C, et al. Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine. Front Immunol. 2019;10:1015. doi:10.3389/fimmu.2019.01015
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang Y, Zhao B, et al. Neoantigen immunotherapeutic-gel combined with TIM-3 blockade effectively restrains orthotopic hepatocellular carcinoma progression. Nano Lett. 2022;22(5):2048–2058. doi:10.1021/acs.nanolett.1c04977
   PubMed Web of Science ®Google Scholar
• Reuven EM, Leviatan Ben-Arye S, Yu H, et al. Biomimetic glyconanoparticle vaccine for cancer immunotherapy. ACS Nano. 2019;13(3):2936–2947. doi:10.1021/acsnano.8b07241
   PubMed Web of Science ®Google Scholar
• Zhou L, Hou B, Wang D, et al. Engineering polymeric prodrug nanoplatform for vaccination immunotherapy of cancer. Nano Lett. 2020;20(6):4393–4402. doi:10.1021/acs.nanolett.0c01140
   PubMed Web of Science ®Google Scholar
• Ye X, Liang X, Chen Q, et al. Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS Nano. 2019;13(3):2956–2968. doi:10.1021/acsnano.8b07371
   PubMed Web of Science ®Google Scholar
• Kanemura H, Hayashi H, Tomida S, et al. The tumor immune microenvironment and frameshift neoantigen load determine response to PD-L1 blockade in extensive-stage SCLC. JTO Clin Res Rep. 2022;3(8):100373. doi:10.1016/j.jtocrr.2022.100373
   PubMedGoogle Scholar
• Badr MY, Halwani AA, Odunze U, et al. The topical ocular delivery of rapamycin to posterior eye tissues and the suppression of retinal inflammatory disease. Int J Pharm. 2022;621:121755. doi:10.1016/j.ijpharm.2022.121755
   PubMedGoogle Scholar
• Dumauthioz N, Labiano S, Romero P. Tumor resident memory T Cells: new players in immune surveillance and therapy. Front Immunol. 2018;9:2076. doi:10.3389/fimmu.2018.02076
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas. Gastroenterology. 2017;153(4):1107–1119 e10. doi:10.1053/j.gastro.2017.06.017
   PubMed Web of Science ®Google Scholar
• Kim HD, Song GW, Park S, et al. Association between expression level of PD1 by tumor-infiltrating CD8(+) T cells and features of hepatocellular carcinoma. Gastroenterology. 2018;155(6):1936–1950 e17. doi:10.1053/j.gastro.2018.08.030
   PubMed Web of Science ®Google Scholar
• Lv H, Lv G, Chen C, et al. NAD(+) metabolism maintains inducible PD-L1 expression to drive tumor immune evasion. Cell Metab. 2021;33(1):110–127 e5. doi:10.1016/j.cmet.2020.10.021
   PubMed Web of Science ®Google Scholar
• Guo W, Gao H, Li H, et al. Self-assembly of a multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA potentiate immune checkpoint therapy for colorectal cancer. ACS Appl Mater Interfaces. 2022;14(28):31634–31644. doi:10.1021/acsami.2c06001
   PubMed Web of Science ®Google Scholar
• Nguyen NT, Huang K, Zeng H, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16(12):1424–1434. doi:10.1038/s41565-021-00982-5
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Su HL, Wang HL, et al. Tumor chemo-radiotherapy with rod-shaped and spherical gold nano probes: shape and active targeting both matter. Theranostics. 2019;9(7):1893–1908. doi:10.7150/thno.30523
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287. doi:10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Tran E, Robbins PF, Lu YC, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255–2262. doi:10.1056/NEJMoa1609279
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548–2560. doi:10.7150/ijbs.34213
   PubMed Web of Science ®Google Scholar
• Meir R, Shamalov K, Betzer O, et al. Nanomedicine for cancer immunotherapy: tracking cancer-specific T-cells in vivo with gold nanoparticles and CT imaging. ACS Nano. 2015;9(6):6363–6372. doi:10.1021/acsnano.5b01939
   PubMed Web of Science ®Google Scholar
• Tang L, Zheng Y, Melo MB, et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707–716. doi:10.1038/nbt.4181
   PubMed Web of Science ®Google Scholar
• Zakeri N, Hall A, Swadling L, et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat Commun. 2022;13(1):1372. doi:10.1038/s41467-022-29012-1
   PubMed Web of Science ®Google Scholar
• Xu J, Lv J, Zhuang Q, et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020;15(12):1043–1052. doi:10.1038/s41565-020-00781-4
   PubMed Web of Science ®Google Scholar
• Lee B, Lee K, Panda S, et al. Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours. Nat Biomed Eng. 2018;2(7):497–507. doi:10.1038/s41551-018-0252-8
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang Y, He Z, et al. Successive site translocating inoculation improved T cell responses elicited by a DNA vaccine encoding SARS-CoV-2 S protein. Front Immunol. 2022;13:875236. doi:10.3389/fimmu.2022.875236
   PubMed Web of Science ®Google Scholar
• Song H, Su Q, Nie Y, et al. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy. Acta Biomater. 2023;158:535–546. doi:10.1016/j.actbio.2022.12.070
   PubMed Web of Science ®Google Scholar
• Bald T, Krummel MF, Smyth MJ, Barry KC. The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol. 2020;21(8):835–847. doi:10.1038/s41590-020-0728-z
   PubMed Web of Science ®Google Scholar
• Wege AK, Weber F, Kroemer A, Ortmann O, Nimmerjahn F, Brockhoff G. IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget. 2017;8(2):2731–2744. doi:10.18632/oncotarget.13159
   PubMedGoogle Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118. doi:10.1038/cr.2016.151
   PubMed Web of Science ®Google Scholar
• Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: th17 and Treg cells in cancer and autoimmunity. Cell Mol Immunol. 2018;15(5):458–469. doi:10.1038/s41423-018-0004-4
   PubMed Web of Science ®Google Scholar
• Ohue Y, Nishikawa H.Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?. Cancer Sci. 2019;110(7):2080–2089. doi:10.1111/cas.14069
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019;49(8):1140–1146. doi:10.1002/eji.201847659
   PubMed Web of Science ®Google Scholar
• Liu G, Bi Y, Xue L, et al. Dendritic cell SIRT1-HIF1alpha axis programs the differentiation of CD4+ T cells through IL-12 and TGF-beta 1. Proc Natl Acad Sci U S A. 2015;112(9):E957–65. doi:10.1073/pnas.1420419112
   PubMed Web of Science ®Google Scholar
• Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474. doi:10.3389/fimmu.2018.01474
   PubMed Web of Science ®Google Scholar
• Stier MT, Zhang J, Goleniewska K, et al. IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow. J Exp Med. 2018;215(1):263–281. doi:10.1084/jem.20170449
   PubMed Web of Science ®Google Scholar
• Ponzetti M, Ucci A, Puri C, et al. Effects of osteoblast-derived extracellular vesicles on aggressiveness, redox status and mitochondrial bioenergetics of MNNG/HOS osteosarcoma cells. Front Oncol. 2022;12:983254. doi:10.3389/fonc.2022.983254
   PubMed Web of Science ®Google Scholar
• Wei B, Pan J, Yuan R, et al. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy. Nano Lett. 2021;21(10):4231–4240. doi:10.1021/acs.nanolett.1c00209
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shen R, Vuong I, et al. Multi-step screening of DNA/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression. Nat Commun. 2022;13(1):4282. doi:10.1038/s41467-022-31993-y
   PubMed Web of Science ®Google Scholar
• Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):7. doi:10.1186/s13045-020-01014-w
   PubMed Web of Science ®Google Scholar
• Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. doi:10.1186/s12943-020-01238-x
   PubMed Web of Science ®Google Scholar
• Biber G, Sabag B, Raiff A, et al. Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity. EMBO Mol Med. 2022;14(1):e14073. doi:10.15252/emmm.202114073
   PubMed Web of Science ®Google Scholar
• Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73. doi:10.1186/s13045-021-01083-5
   PubMed Web of Science ®Google Scholar
• Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O, Borrego F. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278. doi:10.3389/fimmu.2019.02278
   PubMed Web of Science ®Google Scholar
• Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32(2):135–154. doi:10.1016/j.ccell.2017.06.009
   PubMed Web of Science ®Google Scholar
• Sawyer AJ, Garand M, Chaussabel D, Feng CG. Transcriptomic profiling identifies neutrophil-specific upregulation of cystatin F as a marker of acute inflammation in humans. Front Immunol. 2021;12:634119. doi:10.3389/fimmu.2021.634119
   PubMed Web of Science ®Google Scholar
• Chen C, Ai QD, Chu SF, Zhang Z, Chen NH. NK cells in cerebral ischemia. Biomed Pharmacother. 2019;109:547–554. doi:10.1016/j.biopha.2018.10.103
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1
   PubMed Web of Science ®Google Scholar
• Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg. 1986;64(5):743–749. doi:10.3171/jns.1986.64.5.0743
   PubMed Web of Science ®Google Scholar
• Xiang Z, Liu Y, Zheng J, et al. Targeted activation of human Vgamma9Vdelta2-T cells controls Epstein-Barr virus-induced B cell lymphoproliferative disease. Cancer Cell. 2014;26(4):565–576. doi:10.1016/j.ccr.2014.07.026
   PubMed Web of Science ®Google Scholar
• Bergmann C, Strauss L, Zeidler R, Lang S, Whiteside TL. Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res. 2007;67(18):8865–8873. doi:10.1158/0008-5472.CAN-07-0767
   PubMed Web of Science ®Google Scholar
• Chen YP, Yin JH, Li WF, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30(11):1024–1042. doi:10.1038/s41422-020-0374-x
   PubMed Web of Science ®Google Scholar
• Hou L, Tian C, Yan Y, Zhang L, Zhang H, Zhang Z. Manganese-based nanoactivator optimizes cancer immunotherapy via enhancing innate immunity. ACS Nano. 2020;14(4):3927–3940. doi:10.1021/acsnano.9b06111
   PubMed Web of Science ®Google Scholar
• Voli F, Valli E, Lerra L, et al. Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion. Cancer Res. 2020;80(19):4129–4144. doi:10.1158/0008-5472.CAN-20-0471
   PubMed Web of Science ®Google Scholar
• Vulpis E, Loconte L, Peri A, et al. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: dual role in cancer immunosurveillance. J Extracell Vesicles. 2022;11(1):e12176. doi:10.1002/jev2.12176
   PubMed Web of Science ®Google Scholar
• Wu X, Yang H, Chen X, et al. Nano-herb medicine and PDT induced synergistic immunotherapy for colon cancer treatment. Biomaterials. 2021;269:120654. doi:10.1016/j.biomaterials.2021.120654
   PubMed Web of Science ®Google Scholar
• Perozziello G, La Rocca R, Cojoc G, et al. Microfluidic devices modulate tumor cell line susceptibility to NK cell recognition. Small. 2012;8(18):2886–2894. doi:10.1002/smll.201200160
   PubMed Web of Science ®Google Scholar
• Jiang CT, Chen KG, Liu A, et al. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. Nat Commun. 2021;12(1):1359. doi:10.1038/s41467-021-21497-6
   PubMed Web of Science ®Google Scholar
• Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv. 2020;6(27):eaba8564. doi:10.1126/sciadv.aba8564
   PubMed Web of Science ®Google Scholar
• Deng G, Sun Z, Li S, et al. Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano. 2018;12(12):12096–12108. doi:10.1021/acsnano.8b05292
   PubMed Web of Science ®Google Scholar
• Lin X, Li F, Gu Q, et al. Gold-seaurchin based immunomodulator enabling photothermal intervention and alphaCD16 transfection to boost NK cell adoptive immunotherapy. Acta Biomater. 2022;146:406–420. doi:10.1016/j.actbio.2022.04.029
   PubMed Web of Science ®Google Scholar
• Deng M, Guo R, Zang S, et al. pH-triggered copper-free click reaction-mediated micelle aggregation for enhanced tumor retention and elevated immuno-chemotherapy against melanoma. ACS Appl Mater Interfaces. 2021;13(15):18033–18046. doi:10.1021/acsami.1c02567
   PubMed Web of Science ®Google Scholar
• Liu JQ, Zhang C, Zhang X, et al. Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J Control Release. 2022;345:306–313. doi:10.1016/j.jconrel.2022.03.021
   PubMed Web of Science ®Google Scholar
• Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85–100. doi:10.1038/s41571-020-0426-7
   PubMed Web of Science ®Google Scholar
• Fang F, Xie S, Chen M, et al. Advances in NK cell production. Cell Mol Immunol. 2022;19(4):460–481. doi:10.1038/s41423-021-00808-3
   PubMed Web of Science ®Google Scholar
• Terren I, Orrantia A, Astarloa-Pando G, Amarilla-Irusta A, Zenarruzabeitia O, Borrego F. Cytokine-induced memory-like NK cells: from the basics to clinical applications. Front Immunol. 2022;13:884648. doi:10.3389/fimmu.2022.884648
   PubMed Web of Science ®Google Scholar
• Zhu P, Lu T, Wu J, et al. Gut microbiota drives macrophage-dependent self-renewal of intestinal stem cells via niche enteric serotonergic neurons. Cell Res. 2022;32(6):555–569. doi:10.1038/s41422-022-00645-7
   PubMed Web of Science ®Google Scholar
• Zhang R, Feng L, Dong Z, et al. Glucose & oxygen exhausting liposomes for combined cancer starvation and hypoxia-activated therapy. Biomaterials. 2018;162:123–131. doi:10.1016/j.biomaterials.2018.02.004
   PubMed Web of Science ®Google Scholar
• Zhang D, Xu Z, Tao T, et al. Retraction notice to” Modification of TAK1 by O-linked N-acetylglucosamine facilitates TAK1 activation and promotes M1 macrophage polarization. Cell Signal. 2017;36(36):267. doi:10.1016/j.cellsig.2017.05.016
   PubMedGoogle Scholar
• Genova C, Dellepiane C, Carrega P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12:799455. doi:10.3389/fimmu.2021.799455
   PubMed Web of Science ®Google Scholar
• Jiao S, Subudhi SK, Aparicio A, et al. Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179(5):1177–1190 e13. doi:10.1016/j.cell.2019.10.029
   PubMed Web of Science ®Google Scholar
• Kubelka CF, Ruppel A, Gemsa D, Krammer PH. In vivo activation of macrophages by T cell-derived lymphokines: killing of tumor cells and schistosomula of Schistosoma mansoni. Immunobiology. 1986;171(4–5):311–319. doi:10.1016/S0171-2985(86)80063-8
   PubMed Web of Science ®Google Scholar
• Guo Q, Li X, Zhou W, et al. Sequentially triggered bacterial outer membrane vesicles for macrophage metabolism modulation and tumor metastasis suppression. ACS Nano. 2021;15(8):13826–13838. doi:10.1021/acsnano.1c05613
   PubMed Web of Science ®Google Scholar
• Czimmerer Z, Halasz L, Daniel B, et al. The epigenetic state of IL-4-polarized macrophages enables inflammatory cistromic expansion and extended synergistic response to TLR ligands. Immunity. 2022;55(11):2006–2026 e6. doi:10.1016/j.immuni.2022.10.004
   PubMed Web of Science ®Google Scholar
• Wang H, Ding T, Guan J, et al. Interrogation of folic acid-functionalized nanomedicines: the regulatory roles of plasma proteins reexamined. ACS Nano. 2020;14(11):14779–14789. doi:10.1021/acsnano.0c02821
   PubMed Web of Science ®Google Scholar
• Fei Y, Wang Z, Huang M, et al. MiR −155 regulates M2 polarization of hepatitis B virus-infected tumour-associated macrophages which in turn regulates the malignant progression of hepatocellular carcinoma. J Viral Hepat. 2023;30:417–426. doi:10.1111/jvh.13809
   PubMed Web of Science ®Google Scholar
• Tirella A, Kloc-Muniak K, Good L, et al. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment. Int J Pharm. 2019;561:114–123. doi:10.1016/j.ijpharm.2019.02.032
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu X, Ma W, et al. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials. 2021;265:120456. doi:10.1016/j.biomaterials.2020.120456
   PubMed Web of Science ®Google Scholar
• Li K, Lin C, He Y, et al. Engineering of cascade-responsive nanoplatform to inhibit lactate efflux for enhanced tumor chemo-immunotherapy. ACS Nano. 2020;14(10):14164–14180. doi:10.1021/acsnano.0c07071
   PubMed Web of Science ®Google Scholar
• Rong L, Zhang Y, Li WS, Su Z, Fadhil JI, Zhang C. Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy. Biomaterials. 2019;225:119515. doi:10.1016/j.biomaterials.2019.119515
   PubMed Web of Science ®Google Scholar
• Song M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward m1-like phenotype and attenuating tumor hypoxia. ACS Nano. 2016;10(1):633–647. doi:10.1021/acsnano.5b06779
   PubMed Web of Science ®Google Scholar
• Ramesh A, Kumar S, Nandi D, Kulkarni A. CSF1R- and SHP2-inhibitor-loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor-associated macrophages. Adv Mater. 2019;31(51):e1904364. doi:10.1002/adma.201904364
   PubMed Web of Science ®Google Scholar
• Abdel-Bar HM, Walters AA, Lim Y, et al. An ”eat me” combinatory nano-formulation for systemic immunotherapy of solid tumors. Theranostics. 2021;11(18):8738–8754. doi:10.7150/thno.56936
   PubMed Web of Science ®Google Scholar
• Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol. 2022;15(1):110. doi:10.1186/s13045-022-01328-x
   PubMed Web of Science ®Google Scholar
• Liu M, Liu J, Liang Z, et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells. 2022;11(22):3692. doi:10.3390/cells11223692
   PubMed Web of Science ®Google Scholar
• Chang DK, Peterson E, Sun J, et al. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016;5(3):e1090075. doi:10.1080/2162402X.2015.1090075
   PubMed Web of Science ®Google Scholar
• Sauer T, Parikh K, Sharma S, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021;138(4):318–330. doi:10.1182/blood.2020008221
   PubMed Web of Science ®Google Scholar
• Albinger N, Pfeifer R, Nitsche M, et al. Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer J. 2022;12(4):61. doi:10.1038/s41408-022-00660-2
   PubMed Web of Science ®Google Scholar
• Schepisi G, Gianni C, Palleschi M, et al. The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) Cell and Macrophage (CAR-M) therapy against breast cancer. Cancers (Basel). 2023;15(5):1597. doi:10.3390/cancers15051597
   PubMed Web of Science ®Google Scholar
• Tang Y, Yin H, Zhao X, et al. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res. 2022;41(1):2. doi:10.1186/s13046-021-02214-z
   PubMed Web of Science ®Google Scholar
• Chen Y, Yu Z, Tan X, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605. doi:10.1016/j.biopha.2021.111605
   PubMed Web of Science ®Google Scholar
• Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36–50. doi:10.1016/j.cmet.2019.06.001
   PubMed Web of Science ®Google Scholar
• Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. Annu Rev Immunol. 2015;33:355–391. doi:10.1146/annurev-immunol-032414-112103
   PubMed Web of Science ®Google Scholar
• Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327–336. doi:10.1038/nri2303
   PubMed Web of Science ®Google Scholar
• Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPalpha Immune Checkpoint. Immunity. 2020;52(5):742–752. doi:10.1016/j.immuni.2020.04.011
   PubMed Web of Science ®Google Scholar
• Veillette A, Chen J. SIRPalpha-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 2018;39(3):173–184. doi:10.1016/j.it.2017.12.005
   PubMed Web of Science ®Google Scholar
• Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–953. doi:10.1038/s41587-020-0462-y
   PubMed Web of Science ®Google Scholar
• Pereira BA, Vennin C, Papanicolaou M, et al. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer. 2019;5(11):724–741. doi:10.1016/j.trecan.2019.09.010
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S, Hamberger F, Ravichandra A, et al.. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021;131(11). doi:10.1172/JCI146987
   Web of Science ®Google Scholar
• Nallasamy P, Nimmakayala RK, Karmakar S, et al. Pancreatic tumor microenvironment factor promotes cancer stemness via SPP1-CD44 axis. Gastroenterology. 2021;161(6):1998–2013 e7. doi:10.1053/j.gastro.2021.08.023
   PubMed Web of Science ®Google Scholar
• Fiori ME, Di Franco S, Villanova L, Bianca P, Stassi G, De Maria R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer. 2019;18(1):70. doi:10.1186/s12943-019-0994-2
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3(6):422–433. doi:10.1038/nrc1094
   PubMed Web of Science ®Google Scholar
• Dominguez CX, Muller S, Keerthivasan S, et al. Single-Cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10(2):232–253. doi:10.1158/2159-8290.CD-19-0644
   PubMed Web of Science ®Google Scholar
• Bernard V, Semaan A, Huang J, et al. Single-cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res. 2019;25(7):2194–2205. doi:10.1158/1078-0432.CCR-18-1955
   PubMed Web of Science ®Google Scholar
• Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 2019;9(8):1102–1123. doi:10.1158/2159-8290.CD-19-0094
   PubMed Web of Science ®Google Scholar
• Hosein AN, Huang H, Wang Z, et al.. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight. 2019;5:16.
   Google Scholar
• Peng J, Sun BF, Chen CY, et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 2019;29(9):725–738. doi:10.1038/s41422-019-0195-y
   PubMed Web of Science ®Google Scholar
• Zhao XX, Li LL, Zhao Y, et al. In situ self-assembled nanofibers precisely target cancer-associated fibroblasts for improved tumor imaging. Angew Chem Int Ed Engl. 2019;58(43):15287–15294. doi:10.1002/anie.201908185
   PubMed Web of Science ®Google Scholar
• Zhang G, He Y, Liu Y, Du Y, Yang C, Gao F. Reduced hyaluronan cross-linking induces breast cancer malignancy in a CAF-dependent manner. Cell Death Dis. 2021;12(6):586. doi:10.1038/s41419-021-03875-6
   PubMed Web of Science ®Google Scholar
• Kim DJ, Dunleavey JM, Xiao L, et al. Suppression of TGFbeta-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br J Cancer. 2018;118(10):1359–1368. doi:10.1038/s41416-018-0072-3
   PubMed Web of Science ®Google Scholar
• Luo X, Fong ELS, Zhu C, et al. Hydrogel-based colorectal cancer organoid co-culture models. Acta Biomater. 2021;132:461–472. doi:10.1016/j.actbio.2020.12.037
   PubMed Web of Science ®Google Scholar
• Kozakowski N, Hartmann C, Klingler HC, et al. Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. Target Oncol. 2014;9(4):359–366. doi:10.1007/s11523-013-0298-1
   PubMed Web of Science ®Google Scholar
• Harryvan TJ, Hawinkels L, Mini-tumor W, et al. A novel pancreatic cancer mini-tumor model to study desmoplasia and myofibroblastic cancer-associated fibroblast differentiation. Gastro Hep Adv. 2022;1(4):678–681. doi:10.1016/j.gastha.2022.04.019
   PubMedGoogle Scholar
• Liu G, Sun Z, Fu Z, Ma L, Wang X. Temperature sensing and bio-imaging applications based on polyethylenimine/CaF(2) nanoparticles with upconversion fluorescence. Talanta. 2017;169:181–188. doi:10.1016/j.talanta.2017.03.054
   PubMed Web of Science ®Google Scholar
• Karthickraja D, Kumar GA, Sardar DK, et al. Fabrication of Nd(3+) and Yb(3+) doped NIR emitting nano fluorescent probe: a candidate for bioimaging applications. Mater Sci Eng C Mater Biol Appl. 2021;125:112095. doi:10.1016/j.msec.2021.112095
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229. doi:10.1053/j.gastro.2013.10.013
   PubMed Web of Science ®Google Scholar
• Kieffer Y, Hocine HR, Gentric G, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330–1351. doi:10.1158/2159-8290.CD-19-1384
   PubMed Web of Science ®Google Scholar
• Feng J, Xu M, Wang J, et al. Sequential delivery of nanoformulated alpha-mangostin and triptolide overcomes permeation obstacles and improves therapeutic effects in pancreatic cancer. Biomaterials. 2020;241:119907. doi:10.1016/j.biomaterials.2020.119907
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang H, Hsiao CH, et al. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Biomaterials. 2018;159:215–228. doi:10.1016/j.biomaterials.2018.01.014
   PubMed Web of Science ®Google Scholar
• Yu Q, Qiu Y, Li J, et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J Control Release. 2020;321:564–575. doi:10.1016/j.jconrel.2020.02.040
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Barkauskas DS, et al. Co-inhibition of CD73 and A2AR Adenosine signaling improves anti-tumor immune responses. Cancer Cell. 2016;30(3):391–403. doi:10.1016/j.ccell.2016.06.025
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626–5635. doi:10.1158/1078-0432.CCR-13-0545
   PubMed Web of Science ®Google Scholar
• Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, et al. Netrin G1 promotes pancreatic tumorigenesis through cancer-associated fibroblast-driven nutritional support and immunosuppression. Cancer Discov. 2021;11(2):446–479. doi:10.1158/2159-8290.CD-20-0775
   PubMed Web of Science ®Google Scholar
• Ogier C, Colombo PE, Bousquet C, et al. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Lett. 2018;432:227–236. doi:10.1016/j.canlet.2018.06.023
   PubMed Web of Science ®Google Scholar
• Peran I, Dakshanamurthy S, McCoy MD, et al. Cadherin 11 promotes immunosuppression and extracellular matrix deposition to support growth of pancreatic tumors and resistance to gemcitabine in mice. Gastroenterology. 2021;160(4):1359–1372 e13. doi:10.1053/j.gastro.2020.11.044
   PubMed Web of Science ®Google Scholar
• Zhang Z, Karthaus WR, Lee YS, et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell. 2020;38(2):279–296 e9. doi:10.1016/j.ccell.2020.06.005
   PubMed Web of Science ®Google Scholar
• Purcell JW, Tanlimco SG, Hickson J, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 2018;78(14):4059–4072. doi:10.1158/0008-5472.CAN-18-0327
   PubMed Web of Science ®Google Scholar
• Cui J, Dean D, Wei R, Hornicek FJ, Ulmert D, Duan Z. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. J Orthop Res. 2020;38(11):2362–2372. doi:10.1002/jor.24848
   PubMed Web of Science ®Google Scholar
• Kato M, Placencio-Hickok VR, Madhav A, et al. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene. 2019;38(5):716–730. doi:10.1038/s41388-018-0461-3
   PubMed Web of Science ®Google Scholar
• Hutton C, Heider F, Blanco-Gomez A, et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021;39(9):1227–1244 e20. doi:10.1016/j.ccell.2021.06.017
   PubMed Web of Science ®Google Scholar
• Mezawa Y, Daigo Y, Takano A, et al. CD26 expression is attenuated by TGF-beta and SDF-1 autocrine signaling on stromal myofibroblasts in human breast cancers. Cancer Med. 2019;8(8):3936–3948. doi:10.1002/cam4.2249
   PubMed Web of Science ®Google Scholar
• Helms EJ, Berry MW, Chaw RC, et al. Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts. Cancer Discov. 2022;12(2):484–501. doi:10.1158/2159-8290.CD-21-0601
   PubMed Web of Science ®Google Scholar
• Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer. 2022;8(7):527–555. doi:10.1016/j.trecan.2022.03.001
   PubMed Web of Science ®Google Scholar
• Papait A, Romoli J, Stefani FR, et al. Fight the Cancer, Hit the CAF!. Cancers (Basel). 2022;14(15):3570. doi:10.3390/cancers14153570
   PubMed Web of Science ®Google Scholar
• Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218. doi:10.1038/s41392-021-00641-0
   PubMed Web of Science ®Google Scholar